Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 1(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03328026Phase 1Completed

Combination Study of SV-BR-1-GM With Retifanlimab

Role: collaborator

NCT06175221Phase 2Terminated

Autologous TLPO Vaccine Basket

Role: collaborator

NCT02301611Phase 2Completed

Phase IIB TL + YCWP + DC in Melanoma

Role: collaborator

NCT03761914Phase 1Completed

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Role: collaborator

NCT02678741Phase 1Completed

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Role: collaborator

All 5 trials loaded